Blood product administration during high risk neuroblastoma therapy

References

• Harlan L, Greene A, Clegg L, et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol. 2005;23(36):9079–9088. doi:10.1200/JCO.2004.00.1297.
   PubMed Web of Science ®Google Scholar
• Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19(5):428–432. doi:10.1097/00043426-199709000-00004.
   PubMed Web of Science ®Google Scholar
• Kufe DW, Pollock RE, Weichselbaum R, et al. Holland-Frei Cancer Medicine. Ontario, Canada: BC Decker; 2003.
   Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165–1173. doi:10.1056/NEJM199910143411601.
   PubMed Web of Science ®Google Scholar
• Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–3017. doi:10.1200/JCO.2014.59.4648.
   PubMed Web of Science ®Google Scholar
• Simon T, Berthold F, Borkhardt A, et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578–583. doi:10.1002/pbc.22693.
   PubMed Web of Science ®Google Scholar
• Park JR, Kreissman SG, London WB. A phase 3 randomized clinical trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cell as consolidation therapy for high-risk neuroblastoma: A Children’s Oncology Group study. Journal of Clinical Oncology. 2016;34:18.
   Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334. doi:10.1056/NEJMoa0911123.
   PubMed Web of Science ®Google Scholar
• Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16(Suppl 3):12–18. doi:10.1634/theoncologist.2011-S3-12.
   PubMed Web of Science ®Google Scholar
• Wu Y, Aravind S, Ranganathan G, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009;31 Pt 2:2416–2432. doi:10.1016/j.clinthera.2009.11.020.
   PubMed Web of Science ®Google Scholar
• Keenan H, Foster C, Bratton S. Social factors associated with prolonged hospitalization among diabetic children. Pediatrics. 2002;109(1):40–44. doi:10.1542/peds.109.1.40.
   PubMed Web of Science ®Google Scholar
• Russell J, Colevas A. Adverse event monitoring in oncology clinical trials. Clin Invest. 2013;3(12):1157–1165. doi:10.4155/cli.13.111.
   Google Scholar
• Common Terminology Criteria for Adverse Events. National Cancer Institute. US Department of Health and Human Services, NIH; 2009. https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf
   Google Scholar
• Soni S, Pai V, Gross TG, et al. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Pediatr Transplant. 2014;18(2):217–220. doi:10.1111/petr.12202.
   PubMed Web of Science ®Google Scholar
• Ladenstein RL, Poetschger U, R L, et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. J Clin Oncol. 2011;29(18_suppl):2. doi:10.1200/jco.2011.29.18_suppl.2.
   Web of Science ®Google Scholar
• Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phy. 1986;12(11):2047–2050. doi:10.1016/0360-3016(86)90146-X.
   PubMed Web of Science ®Google Scholar
• Hofmann A, Ozawa S, Farrugia A, et al. Economic considerations on transfusion medicine and patient blood management.. Best Pract Res Clin Anaesthesiol. 2013;27:59–68. doi:10.1016/j.bpa.2013.02.001.
   PubMedGoogle Scholar
• Nottage K, Gurney JG, Smeltzer M, et al. Trends in transfusion burden among long-term survivors of childhood hematological malignancies. Leuk Lymphoma. 2013;54:1719–1723. doi:10.3109/10428194.2012.750724.
   PubMed Web of Science ®Google Scholar
• Trentino KM, Farmer SL, Swain SG, et al. Increased hospital costs associated with red blood cell transfusion. Transfusion. 2015;55(5):1082–1089. doi:10.1111/trf.12958.
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–1936. doi:10.1182/blood-2003-06-1919.
   PubMed Web of Science ®Google Scholar
• de Ville de Goyet M, Moniotte S, Robert A, et al. Iron overload in children undergoing cancer treatments. Pediatr Blood Cancer. 2013;60:1982–1987. doi:10.1002/pbc.24705.
   PubMed Web of Science ®Google Scholar
• Ruccione KS, Wood JC, Sposto R, et al. Characterization of transfusion-derived iron deposition in childhood cancer survivors. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the. Am Soc Prev Oncol. 2014;23(9):1913–1919. doi:10.1158/1055-9965.EPI-14-0292.
   Google Scholar
• Sait S, Zaghloul N, Patel A, et al. Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy. Pediatr Blood Cancer. 2014;61:2319–2320. doi:10.1002/pbc.25189.
   PubMedGoogle Scholar
• Halonen P, Mattila J, Suominen P, et al. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. Pediatrics. 2003;111(1):91–96. doi:10.1542/peds.111.1.91.
   PubMed Web of Science ®Google Scholar
• Schempp A, Lee J, Kearney S, et al. Iron overload in survivors of childhood cancer. J Pediatr Hematol Oncol. 2016;38(1):27–31. doi:10.1097/MPH.0000000000000444.
   PubMed Web of Science ®Google Scholar
• Trovillion EM, Schubert L, Dietz AC. Iron overload in survivors of childhood cancer. J Pediatr Hematol Oncol. 2018;40:396–400. doi:10.1097/MPH.0000000000000887.
   PubMed Web of Science ®Google Scholar
• Unal S, Cetin M, Hazirolan T, et al. Number of erythrocyte transfusions is more predictive than serum ferritin in estimation of cardiac iron loading in pediatric patients with acute lymphoblastic leukemia. Leuk Res. 2014;38(8):882–885. doi:10.1016/j.leukres.2014.05.002.
   PubMed Web of Science ®Google Scholar
• Laverdiere C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101(16):1131–1140. doi:10.1093/jnci/djp230.
   PubMed Web of Science ®Google Scholar
• Norsker FN, Rechnitzer C, Cederkvist L, et al. Somatic late effects in 5-year survivors of neuroblastoma: a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study. Int J Cancer. 2018;143:3083–3096.
   PubMed Web of Science ®Google Scholar
• Landier W, Armenian SH, Lee J, et al. Yield of screening for long-term complications using the Children's Oncology Group long-term follow-up guidelines. J Clin Oncol. 2012;30(35):4401–4408. doi:10.1200/JCO.2012.43.4951.
   PubMed Web of Science ®Google Scholar
• Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:Cd002042.
   PubMedGoogle Scholar
• Estcourt LJ, Malouf R, Trivella M, et al. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Cochrane Database Syst Rev. 2017;1:Cd011305.
   PubMedGoogle Scholar